A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

The Institution and Principal Investigator (named in Article 2 below) shall perform the Study in accordance with the terms of this Agreement and the final protocol, including as it may be amended in accordance with the terms of this Agreement, for the Study entitled “A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)” MK-3475-A18-0015 (the "Protocol") which is attached as Exhibit A and incorporated into this Agreement by reference. Institution certifies that, to its best knowledge, its facilities and patient population are adequate to perform the Study contemplated by this Agreement and the Protocol. Sponsor, GOG, Institution and Principal Investigator (named in Article 2 below) agree that all aspects of the Study will be conducted in conformity with all applicable federal, state and local laws and regulations, including generally accepted standards of good clinical practice.